Jennison Associates LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Jennison Associates LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 8,926 shares of the medical equipment provider's stock, valued at approximately $980,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its holdings in Lantheus by 10.4% during the first quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider's stock worth $2,347,000 after acquiring an additional 3,560 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after buying an additional 389,828 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Lantheus by 30.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider's stock valued at $3,116,000 after buying an additional 11,696 shares in the last quarter. 2Xideas AG acquired a new position in Lantheus during the first quarter worth $10,642,000. Finally, Tidal Investments LLC raised its position in Lantheus by 68.1% during the first quarter. Tidal Investments LLC now owns 27,570 shares of the medical equipment provider's stock worth $1,716,000 after acquiring an additional 11,168 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

LNTH has been the subject of a number of analyst reports. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. JMP Securities lowered their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Truist Financial reissued a "buy" rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $122.50.

Lantheus Stock Performance

NASDAQ:LNTH traded up $3.20 during mid-day trading on Friday, reaching $90.52. 2,014,988 shares of the company's stock were exchanged, compared to its average volume of 1,546,289. The firm has a market capitalization of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The business's fifty day simple moving average is $103.13 and its two-hundred day simple moving average is $96.93.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.